This Army funding opportunity supports investigator-initiated research into toxic exposures affecting military personnel, seeking novel scientific studies to understand health impacts and inform prevention strategies.
This Army award supports melanoma survivorship research, focusing on improving quality of life and long-term outcomes for cancer survivors. It seeks studies addressing post-treatment complications, psychosocial factors, and evidence-based interventions for melanoma patients.
The Army seeks patient-centered research to advance burn treatment and recovery outcomes for military personnel. This funding supports innovative clinical studies and therapeutic approaches to improve care for burn-injured soldiers.
This Army research award supports early-stage investigators studying prostate cancer biology, prevention, or treatment. It funds novel scientific research to advance understanding and clinical outcomes for this disease.
The Army seeks innovative research on military burn treatment and prevention through discovery-phase awards. This funding targets novel solutions to improve clinical outcomes for service members with severe thermal injuries.
This Army Medical Research Acquisition Activity (USAMRAA) award supports physician-led research to advance prostate cancer prevention, detection, and treatment. It funds innovative scientific investigations addressing this significant military and public health challenge.
The Army seeks melanoma research to advance understanding and treatment of this serious cancer. This Scholar Award supports innovative scientific studies that could improve patient outcomes and military medical capabilities.
The Army seeks clinical trial research to advance traumatic brain injury and psychological health treatments for service members. This funding supports evidence-based interventions to improve diagnosis, prevention, and recovery outcomes.
The Army seeks innovative prostate cancer research to advance detection, prevention, or treatment approaches. This Idea Development Award funds early-stage scientific studies addressing unmet clinical needs in prostate cancer management.
This award supports health services research addressing traumatic brain injury and psychological health outcomes in military populations. It seeks evidence-based studies to improve clinical care delivery and patient outcomes for service members.
This award supports clinical trials investigating health outcomes and treatments for service members exposed to toxic substances during military operations. The research aims to establish evidence-based interventions and improve medical care for affected veterans.
Develop advanced applied research concepts for naval space weather and plasma monitoring in the Southern Hemisphere. This challenge seeks game-changing dual-use capabilities that could accelerate Navy/Marine Corps operations while creating commercial and public benefits.
Develop AI-native air interface technology for tactical communication networks in a U.S.-India collaborative challenge. This applied research initiative seeks revolutionary dual-use concepts that could transform military communications and commercial applications.
Develop advanced communications and networking technologies to enable seamless, secure connectivity for distributed naval operations across manned and unmanned platforms. Address challenges like jamming, spectrum limitations, and infrastructure constraints to support real-time command and control.
Develop research resources, datasets, and infrastructure to advance rare cancers research and treatment outcomes. Supports patient tissue repositories, tumor models, data-sharing platforms, and community engagement strategies.
DoD seeks groundbreaking novel concepts to advance rare cancer research and treatment. This concept award supports highly innovative, untested ideas without requiring preliminary data, enabling early-stage exploration of potentially transformative approaches.
The Army seeks applied research innovations in orthopaedic medicine to advance soldier health and readiness. This award funds development of new treatments, devices, or technologies addressing musculoskeletal injuries and combat-related orthopedic conditions.
Seeking early-stage research to develop novel therapies for Duchenne muscular dystrophy across all age groups, from infants to nonambulatory individuals. High-risk/high-reward studies with strong preliminary data that could accelerate near-term clinical outcomes.
DoD seeks development of a multiomic atlas from human bone marrow failure samples to create an open-access research resource. This dataset will enable discoveries advancing understanding of bone marrow failure diseases across the research and clinical community.
This DoD funding supports early-stage rare cancer research ideas with potential for high-impact discoveries. The program welcomes exploratory approaches and accepts preliminary data from related disease studies to advance novel investigation pathways.
The Army seeks orthopaedic clinical research to advance musculoskeletal injury treatment and recovery for military personnel. This award funds innovative studies addressing combat-related and service-connected orthopaedic conditions.
Supports investigator-initiated research advancing bone marrow failure treatments through translational and clinical studies. Funds mature ideas with IND-enabling efforts and correlative research to drive significant patient care improvements.
Support innovative research to understand and cure bone marrow failure diseases through scientifically sound approaches. Open to established and early-career investigators; preliminary data not required.
Fund continuation of military medical R&D projects ranging from late-stage preclinical to clinical research that address Service Member health needs. Supports pharmaceutical, biologic, medical device, and technology development through clinical trials and translational studies.
Accelerate translational research in Duchenne muscular dystrophy toward clinical applications. DoD supports advanced preclinical and clinical studies with flexible funding levels and partnership options to bridge promising discoveries into therapies.